BIOTECH: CEO Irwin Is Out; CFO Jackson Named Interim Leader
Amid legal, manufacturing and financial problems Ra Medical Systems delayed the release of second quarter results.
In a July letter to insurers the California Department of Managed Care, or CDMC, fired a warning shot against association health plans, in what could have wide-reaching impacts for biotechs, life sciences trade groups and other industries.
PROPERTY: Execs’ Offices Take Back Seat to Workers’
Give the best views of the ocean and surrounding landscape to the researchers up front.
Lineage Underwent Corporate Restructuring, Co. to Focus on 3 Programs
BioTime is getting a new name — and a new headquarters.
Shelley Lyford, the CEO of the nonprofit West Health, has been appointed to California’s Master Plan for Aging Stakeholder Advisory Committee.
Virtual Care Opens Lines Of Communication, Healing
Telemedicine is by no means new. But lagging insurance coverage and infrastructure costs prevented wide adoption. That’s changing,
Ionis Having Good Discussions With FDA on Other Therapeutic
Ionis Pharmaceuticals’ drug for a muscle-wasting disease continues to be the company’s main driver of growth, with competition looming.
Amid legal, manufacturing and financial challenges Ra Medical Systems delayed the release of second quarter results and fired its CEO.
A $59 million cancer center on the campus of Scripps Mercy Hospital that’s geared toward the central and southern parts of San Diego recently broke ground.
Expansions By Some Of the Bigger Players Are Expected in Q3
The leasing footprint of San Diego life sciences companies grew by 263,399 square feet in the second quarter, according to report from the brokerage firm JLL.
San Diego-based Halozyme reported $39.1 million in second quarter revenue, an 11% year-over-year increase.
Known for 3-D printed tissues that emulate human organs, Organovo plans to explore a merger, acquisition and other strategic alternatives.
CEO Says Treatment Is Now One Step Closer to the Market
A drug candidate from Cidara Therapeutics aimed at invasive fungal infections hit its mark in midstage clinical trial results, the company recently reported.
MEDICINE: RNA Delivery System Could Bring In $1B, Company has Drug Development Pipeline As Well
Arcturus Therapeutics went through a messy proxy fight last year that saw the removal and then return of its CEO. With that chapter behind it, the company is vying to be a frontrunner in what could be the next big thing in drug development.
Obalon Therapeutics – which makes a gas-filled balloon designed to treat obesity -- recently announced it’s planning a $15 million public stock offering.